CRISPR editing in biological and biomedical investigation

Recently, clustered regularly interspaced short palindromic repeats (CRISPR) based genomic editing technologies have armed researchers with powerful new tools to biological and biomedical investigations. To further improve and expand its functionality, natural, and engineered CRISPR associated nine proteins (Cas9s) have been investigated, various CRISPR delivery strategies have been tested and optimized, and multiple schemes have been developed to ensure precise mammalian genome editing. Benefiting from those in‐depth understanding and further development of CRISPR, versatile CRISPR‐based platforms for genome editing have been rapidly developed to advance investigations in biology and biomedicine. In biological research area, CRISPR has been widely adopted in both fundamental and applied research fields, such as accurate base editing, transcriptional regulation, and genome‐wide screening. In biomedical research area, CRISPR has also shown its extensive applicability in the establishment of animal models for genetic disorders especially those large animals and non‐human primates models, and gene therapy to combat virus infectious diseases, to correct monogenic disorders in vivo or in pluripotent cells. In this prospect article, after highlighting recent developments of CRISPR systems, we outline different applications and current limitations of CRISPR use in biological and biomedical investigation. Finally, we provide a perspective for future development and potential risks of this multifunctional technology.

[1]  Qiang Sun,et al.  Homology-mediated end joining-based targeted integration using CRISPR/Cas9 , 2017, Cell Research.

[2]  George Church,et al.  Optimization of scarless human stem cell genome editing , 2013, Nucleic acids research.

[3]  Yoshio Koyanagi,et al.  Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus , 2013, Scientific Reports.

[4]  Dinggang Shen,et al.  Modeling Rett Syndrome Using TALEN-Edited MECP2 Mutant Cynomolgus Monkeys , 2017, Cell.

[5]  G. Dianov,et al.  Mammalian Base Excision Repair: the Forgotten Archangel , 2013, Nucleic acids research.

[6]  Rodolphe Barrangou,et al.  CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity. , 2014, Molecular cell.

[7]  N. Déglon,et al.  Allele-Specific Silencing of Mutant Huntingtin in Rodent Brain and Human Stem Cells , 2014, PloS one.

[8]  Linda Koch Genetic engineering: In vivo genome editing — growing in strength , 2016, Nature Reviews Genetics.

[9]  E. Wolf,et al.  Efficient production of multi-modified pigs for xenotransplantation by ‘combineering’, gene stacking and gene editing , 2016, Scientific Reports.

[10]  S. Nishikawa,et al.  Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 , 1996, Nature.

[11]  Gang Bao,et al.  Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection , 2014, Proceedings of the National Academy of Sciences.

[12]  R. Prather,et al.  Replacement of Porcine CD163 Scavenger Receptor Cysteine-Rich Domain 5 with a CD163-Like Homolog Confers Resistance of Pigs to Genotype 1 but Not Genotype 2 Porcine Reproductive and Respiratory Syndrome Virus , 2016, Journal of Virology.

[13]  G. Church,et al.  Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies , 2016, Nature Protocols.

[14]  H. Moulton,et al.  Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. , 2012, The American journal of pathology.

[15]  H. Nakauchi,et al.  Blastocyst complementation generates exogenic pancreas in vivo in apancreatic cloned pigs , 2013, Proceedings of the National Academy of Sciences.

[16]  T. Aittokallio,et al.  Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells , 2017, Genome Medicine.

[17]  R. Kucherlapati,et al.  Insertion of DNA sequences into the human chromosomal β-globin locus by homologous recombination , 1985, Nature.

[18]  Q. Xia,et al.  The progress and future of enhancing antiviral capacity by transgenic technology in the silkworm Bombyx mori. , 2014, Insect biochemistry and molecular biology.

[19]  Andrew R. Bassett Editing the genome of hiPSC with CRISPR/Cas9: disease models , 2017, Mammalian Genome.

[20]  Lei Zhang,et al.  A CRISPR-based approach for targeted DNA demethylation , 2016, Cell Discovery.

[21]  Hakho Lee,et al.  Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis , 2015, Cell.

[22]  Daniel G. Anderson,et al.  Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo , 2016, Nature Biotechnology.

[23]  Yilong Li,et al.  Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library , 2013, Nature Biotechnology.

[24]  Daesik Kim,et al.  Highly efficient RNA-guided base editing in mouse embryos , 2017, Nature Biotechnology.

[25]  A. Shibata,et al.  DNA double-strand break repair in a cellular context. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[26]  Kira S. Makarova,et al.  SnapShot: Class 2 CRISPR-Cas Systems , 2017, Cell.

[27]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[28]  A. James,et al.  Transgenic Clustered Regularly Interspaced Short Palindromic Repeat/Cas9-Mediated Viral Gene Targeting for Antiviral Therapy of Bombyx mori Nucleopolyhedrovirus , 2017, Journal of Virology.

[29]  Luke A. Gilbert,et al.  Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.

[30]  J. Joung,et al.  Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition , 2015, Nature Biotechnology.

[31]  H. Niemann,et al.  Efficient production of biallelic GGTA1 knockout pigs by cytoplasmic microinjection of CRISPR/Cas9 into zygotes , 2016, Xenotransplantation.

[32]  Reuben S Harris,et al.  RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. , 2002, Molecular cell.

[33]  Eric S. Lander,et al.  C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector , 2016, Science.

[34]  Yong-Gang Yao,et al.  Experimental primates and non-human primate (NHP) models of human diseases in China: current status and progress. , 2014, Dong wu xue yan jiu = Zoological research.

[35]  Pavel Sumazin,et al.  Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia , 2016, Nature Communications.

[36]  R. Barrangou,et al.  CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes , 2007, Science.

[37]  Hidde L Ploegh,et al.  Inhibition of non-homologous end joining increases the efficiency of CRISPR/Cas9-mediated precise [TM: inserted] genome editing , 2015, Nature Biotechnology.

[38]  E. Rebar,et al.  Genome editing with engineered zinc finger nucleases , 2010, Nature Reviews Genetics.

[39]  S. Prinz,et al.  Isolation of COM1, a new gene required to complete meiotic double-strand break-induced recombination in Saccharomyces cerevisiae. , 1997, Genetics.

[40]  R. Nielsen,et al.  Adaptation and possible ancient interspecies introgression in pigs identified by whole-genome sequencing , 2015, Nature Genetics.

[41]  B. Bennetts,et al.  HIV-1 infection in an individual homozygous for the CCR5 deletion allele , 1997, Nature Medicine.

[42]  David R. Liu,et al.  CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes , 2017, Cell.

[43]  Christopher M. Vockley,et al.  Epigenome editing by a CRISPR/Cas9-based acetyltransferase activates genes from promoters and enhancers , 2015, Nature Biotechnology.

[44]  Yonatan Stelzer,et al.  Editing DNA Methylation in the Mammalian Genome , 2016, Cell.

[45]  Yang Xu,et al.  Homologous recombination in human embryonic stem cells using CRISPR/Cas9 nickase and a long DNA donor template , 2014, Protein & Cell.

[46]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[47]  Hao Yin,et al.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.

[48]  Max A. Horlbeck,et al.  Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation , 2014, Cell.

[49]  B. N. Day,et al.  Production of α-1,3-Galactosyltransferase Knockout Pigs by Nuclear Transfer Cloning , 2002, Science.

[50]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[51]  G. Church,et al.  Supplementary Materials for Genome-wide inactivation of porcine endogenous retroviruses ( PERVs ) , 2015 .

[52]  M. Capecchi,et al.  Altering the genome by homologous recombination. , 1989, Science.

[53]  Wei Zhang,et al.  Dynamic Imaging of Genomic Loci in Living Human Cells by an Optimized CRISPR/Cas System , 2014, Cell.

[54]  K. Davies,et al.  Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches , 2013, Nature Reviews Genetics.

[55]  Eugene V Koonin,et al.  The basic building blocks and evolution of CRISPR-CAS systems. , 2013, Biochemical Society transactions.

[56]  David R. Liu,et al.  Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification , 2014, Nature Biotechnology.

[57]  David R. Liu,et al.  Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage , 2016, Nature.

[58]  R. Barrangou,et al.  Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria , 2012, Proceedings of the National Academy of Sciences.

[59]  G. Kanmogne,et al.  Maraviroc: a review of its use in HIV infection and beyond , 2015, Drug design, development and therapy.

[60]  Tomoyuki Yamaguchi,et al.  Generation of Rat Pancreas in Mouse by Interspecific Blastocyst Injection of Pluripotent Stem Cells , 2010, Cell.

[61]  H. Nauwynck,et al.  Porcine reproductive and respiratory syndrome virus entry into the porcine macrophage. , 2010, The Journal of general virology.

[62]  Chris Millard,et al.  Making the cut , 2013, History of the human sciences.

[63]  Martin J. Aryee,et al.  Engineered CRISPR-Cas9 nucleases with altered PAM specificities , 2015, Nature.

[64]  Nick V Grishin,et al.  A DNA repair system specific for thermophilic Archaea and bacteria predicted by genomic context analysis. , 2002, Nucleic acids research.

[65]  A. Kondo,et al.  Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems , 2016, Science.

[66]  Eugene V Koonin,et al.  Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems , 2011, Biology Direct.

[67]  N. Mueller,et al.  Heart transplantation in baboons using α1,3-galactosyltransferase gene-knockout pigs as donors: initial experience , 2005, Nature Medicine.

[68]  Tetsushi Sakuma,et al.  Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9 , 2014, Nature Communications.

[69]  Kai Li,et al.  Biological and Biomedical Applications of Engineered Nucleases , 2013, Molecular Biotechnology.

[70]  M Pirmohamed,et al.  HIV and drug allergy , 2001, Current opinion in allergy and clinical immunology.

[71]  A. Regev,et al.  Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System , 2015, Cell.

[72]  Qi Zhou,et al.  One-step generation of triple gene-targeted pigs using CRISPR/Cas9 system , 2016, Scientific Reports.

[73]  N. Raab-Traub Novel mechanisms of EBV-induced oncogenesis. , 2012, Current opinion in virology.

[74]  C. Burlak,et al.  Double knockout pigs deficient in N‐glycolylneuraminic acid and Galactose α‐1,3‐Galactose reduce the humoral barrier to xenotransplantation , 2013, Xenotransplantation.

[75]  D. Whelan,et al.  Analysis of Irradiation on the Clinical Effectiveness of Allogenic Tissue When Used for Primary Anterior Cruciate Ligament Reconstruction , 2015, The American journal of sports medicine.

[76]  C. Seeger,et al.  Targeting Hepatitis B Virus With CRISPR/Cas9 , 2014, Molecular therapy. Nucleic acids.

[77]  Andrew Martens,et al.  Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation , 2016, Biology Open.

[78]  John M. Shelton,et al.  Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy , 2016, Science.

[79]  M. M. Rai,et al.  Vertical transmission of nucleopolyhedrovirus in the silkworm, Bombyx mori L. , 2004, Journal of invertebrate pathology.

[80]  J. Haber,et al.  Genetic and physical analysis of double-strand break repair and recombination in Saccharomyces cerevisiae. , 1989, Genetics.

[81]  P. Mali,et al.  Therapeutic genome engineering via CRISPR‐Cas systems , 2017, Wiley interdisciplinary reviews. Systems biology and medicine.

[82]  Jens Boch,et al.  Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors , 2009, Science.

[83]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[84]  Rui Zhang,et al.  Precise base editing in rice, wheat and maize with a Cas9-cytidine deaminase fusion , 2017, Nature Biotechnology.

[85]  M. Capecchi,et al.  Introduction of homologous DNA sequences into mammalian cells induces mutations in the cognate gene , 1986, Nature.

[86]  David A. Scott,et al.  Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity , 2013, Cell.

[87]  Beverly L. Davidson,et al.  CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[88]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[89]  L. Hauser,et al.  Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Hong Wang,et al.  Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9. , 2015, Human molecular genetics.

[91]  J. Coligan,et al.  Efficient gene transfer into the human natural killer cell line, NKL, using the Amaxa nucleofection system. , 2004, Journal of immunological methods.

[92]  D. Ayares,et al.  The role of genetically engineered pigs in xenotransplantation research , 2016, The Journal of pathology.

[93]  Takanori Nakane,et al.  Structure and Engineering of Francisella novicida Cas9 , 2016, Cell.

[94]  A. Archibald,et al.  Precision engineering for PRRSV resistance in pigs: Macrophages from genome edited pigs lacking CD163 SRCR5 domain are fully resistant to both PRRSV genotypes while maintaining biological function , 2017, PLoS pathogens.

[95]  Di Zhang,et al.  CCR5 Gene Disruption via Lentiviral Vectors Expressing Cas9 and Single Guided RNA Renders Cells Resistant to HIV-1 Infection , 2014, PloS one.

[96]  Wei Li,et al.  Generation of PPARγ mono-allelic knockout pigs via zinc-finger nucleases and nuclear transfer cloning , 2011, Cell Research.

[97]  Stan J. J. Brouns,et al.  Evolution and classification of the CRISPR–Cas systems , 2011, Nature Reviews Microbiology.

[98]  Timothy E. Reddy,et al.  CRISPR–Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome , 2017, Nature Biotechnology.

[99]  S. Bultmann,et al.  Site-specific recruitment of epigenetic factors with a modular CRISPR/Cas system , 2017, Nucleus.

[100]  Edward M. Callaway,et al.  In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration , 2016, Nature.

[101]  P. Rouet,et al.  Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. , 1994, Molecular and cellular biology.

[102]  J. Kinney,et al.  Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.

[103]  Jianguo Zhao,et al.  Genome editing revolutionize the creation of genetically modified pigs for modeling human diseases , 2016, Human Genetics.

[104]  N. Grishin,et al.  A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action , 2006, Biology Direct.

[105]  W. Mark Saltzman,et al.  Synthetic DNA delivery systems , 2000, Nature Biotechnology.

[106]  S. Freier,et al.  Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[107]  B. Harper Huntington Disease , 2005, Journal of the Royal Society of Medicine.

[108]  D. Kwon,et al.  Production of α1,3-galactosyltransferase targeted pigs using transcription activator-like effector nuclease-mediated genome editing technology , 2016, Journal of veterinary science.

[109]  Akihiko Kondo,et al.  Targeted base editing in rice and tomato using a CRISPR-Cas9 cytidine deaminase fusion , 2017, Nature Biotechnology.

[110]  J. Veening,et al.  High‐throughput CRISPRi phenotyping identifies new essential genes in Streptococcus pneumoniae , 2017, Molecular systems biology.

[111]  Keiichiro Suzuki,et al.  Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells , 2015, Nature Communications.

[112]  James J. Collins,et al.  Chromatin regulation at the frontier of synthetic biology , 2015, Nature Reviews Genetics.

[113]  Y. Negishi,et al.  Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice. , 2014, Molecular pharmaceutics.

[114]  H. Nagashima,et al.  Generation of α1,3-galactosyltransferase and cytidine monophospho-N-acetylneuraminic acid hydroxylase gene double-knockout pigs , 2015, The Journal of reproduction and development.

[115]  S. Quake,et al.  RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection , 2014, Proceedings of the National Academy of Sciences.

[116]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[117]  Toni Cathomen,et al.  Zinc-finger Nucleases: The Next Generation Emerges. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[118]  Hui Yang,et al.  One-step generation of complete gene knockout mice and monkeys by CRISPR/Cas9-mediated gene editing with multiple sgRNAs , 2017, Cell Research.

[119]  Fan Yang,et al.  RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection , 2014, Proceedings of the National Academy of Sciences.

[120]  N. Martin,et al.  A twin-pronged attack on complex traits , 1997, Nature Genetics.

[121]  S Chandrasegaran,et al.  Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[122]  Jennifer Doudna,et al.  RNA-programmed genome editing in human cells , 2013, eLife.

[123]  Supriya V. Vartak,et al.  Inhibition of nonhomologous end joining to increase the specificity of CRISPR/Cas9 genome editing , 2015, The FEBS journal.

[124]  Ping Yang,et al.  Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance , 2018, Molecular Cancer.

[125]  David A. Scott,et al.  CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus , 2015, Scientific Reports.

[126]  Morgan L. Maeder,et al.  CRISPR RNA-guided activation of endogenous human genes , 2013, Nature Methods.

[127]  W. Ge,et al.  TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys. , 2014, Cell stem cell.

[128]  A. De,et al.  An Inhibitor of Nonhomologous End-Joining Abrogates Double-Strand Break Repair and Impedes Cancer Progression , 2012, Cell.

[129]  George M. Church,et al.  In vivo gene editing in dystrophic mouse muscle and muscle stem cells , 2016, Science.

[130]  Kevin T. Zhao,et al.  Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions , 2017, Nature Biotechnology.

[131]  Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing , 2015, Genome Medicine.

[132]  H. Cui,et al.  Biallelic insertion of a transcriptional terminator via the CRISPR/Cas9 system efficiently silences expression of protein-coding and non-coding RNA genes , 2017, The Journal of Biological Chemistry.

[133]  M. Kay,et al.  Adeno‐associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo , 2010, Hepatology.

[134]  B. Shastry,et al.  SNP alleles in human disease and evolution , 2002, Journal of Human Genetics.

[135]  Stephen Chanock,et al.  Candidate Genes and Single Nucleotide Polymorphisms (SNPs) in the Study of Human Disease , 2002, Disease markers.

[136]  Isaac B. Hilton,et al.  Editing the epigenome: technologies for programmable transcription and epigenetic modulation , 2016, Nature Methods.

[137]  Christopher M. Vockley,et al.  RNA-guided gene activation by CRISPR-Cas9-based transcription factors , 2013, Nature Methods.

[138]  Dongsheng Duan,et al.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy , 2016, Science.

[139]  Jennifer A. Doudna,et al.  Structures of a CRISPR-Cas9 R-loop complex primed for DNA cleavage , 2016, Science.

[140]  Lei Xiao,et al.  Generation of GGTA1 biallelic knockout pigs via zinc-finger nucleases and somatic cell nuclear transfer , 2014, Science China Life Sciences.

[141]  Steven Lin,et al.  Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery , 2014, eLife.

[142]  J. Ervasti,et al.  Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle , 1990, Nature.

[143]  R. Prather,et al.  Gene-edited pigs are protected from porcine reproductive and respiratory syndrome virus , 2016, Nature Biotechnology.

[144]  C. Allis,et al.  Epigenetics: A Landscape Takes Shape , 2007, Cell.

[145]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[146]  S. Nakken,et al.  Computational prediction of the effects of non-synonymous single nucleotide polymorphisms in human DNA repair genes , 2007, Neuroscience.

[147]  David S. Weiss,et al.  Cas9-mediated targeting of viral RNA in eukaryotic cells , 2015, Proceedings of the National Academy of Sciences.

[148]  G. Church,et al.  CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering , 2013, Nature Biotechnology.

[149]  Wei Li,et al.  One-step generation of p53 gene biallelic mutant Cynomolgus monkey via the CRISPR/Cas system , 2014, Cell Research.

[150]  F. Zhang,et al.  Autism-like behaviours and germline transmission in transgenic monkeys overexpressing MeCP2 , 2016, Nature.

[151]  J. Doudna,et al.  RNA-guided genetic silencing systems in bacteria and archaea , 2012, Nature.

[152]  Elo Leung,et al.  A TALE nuclease architecture for efficient genome editing , 2011, Nature Biotechnology.

[153]  Shiyou Zhu,et al.  High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells , 2014, Nature.

[154]  Shihua Li,et al.  CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease , 2017, The Journal of clinical investigation.

[155]  M. Kiebler,et al.  High-efficiency transfection of mammalian neurons via nucleofection , 2007, Nature Protocols.

[156]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[157]  N. He,et al.  Challenges and future expectations of reversed gene therapy. , 2011, Journal of nanoscience and nanotechnology.

[158]  Kenichiro Hata,et al.  Targeted DNA demethylation in vivo using dCas9–peptide repeat and scFv–TET1 catalytic domain fusions , 2016, Nature Biotechnology.

[159]  Nicholas E. Propson,et al.  Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis , 2013, Proceedings of the National Academy of Sciences.

[160]  N. Sternberg,et al.  Recombination in mouse L cells between DNA introduced into cells and homologous chromosomal sequences. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[161]  Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells , 2017, Epigenetics & Chromatin.

[162]  Ding-Shinn Chen,et al.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo , 2014, Molecular therapy. Nucleic acids.

[163]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[164]  L. Symington,et al.  Double-strand break end resection and repair pathway choice. , 2011, Annual review of genetics.

[165]  N. McCarty,et al.  CRISPR Editing in Biological and Biomedical Investigation , 2017, Journal of cellular biochemistry.

[166]  Mazhar Adli,et al.  CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations , 2017, Nature Methods.

[167]  R. Barrangou,et al.  CRISPR/Cas, the Immune System of Bacteria and Archaea , 2010, Science.

[168]  Neville E. Sanjana,et al.  High-throughput functional genomics using CRISPR–Cas9 , 2015, Nature Reviews Genetics.

[169]  F. Issa,et al.  Interspecies Chimerism With Mammalian Pluripotent Stem Cells , 2017 .

[170]  Daesik Kim,et al.  Genome-wide target specificities of CRISPR RNA-guided programmable deaminases , 2017, Nature Biotechnology.

[171]  Daniel H. Haft,et al.  A Guild of 45 CRISPR-Associated (Cas) Protein Families and Multiple CRISPR/Cas Subtypes Exist in Prokaryotic Genomes , 2005, PLoS Comput. Biol..

[172]  T. Kafri,et al.  Gene delivery by lentivirus vectors , 2007, Molecular biotechnology.

[173]  Lei Wang,et al.  Generation of Gene-Modified Cynomolgus Monkey via Cas9/RNA-Mediated Gene Targeting in One-Cell Embryos , 2014, Cell.

[174]  Chun Jimmie Ye,et al.  A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks , 2015, Cell.

[175]  L. Dow Modeling Disease In Vivo With CRISPR/Cas9. , 2015, Trends in molecular medicine.

[176]  Deborah Y. Kwon,et al.  Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC , 2017, Nature Communications.

[177]  赖良学 Generation of PPAR-gamma mono-allelic knockout pigs via zinc-finger nucleases and nuclear transfer cloning , 2011 .

[178]  Y. E. Chen,et al.  RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency , 2016, Nature Communications.

[179]  T. Starzl,et al.  Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys , 2005, Nature Medicine.

[180]  E. Stanley,et al.  A Cas9 Variant for Efficient Generation of Indel-Free Knockin or Gene-Corrected Human Pluripotent Stem Cells , 2016, Stem cell reports.

[181]  T. VandenDriessche,et al.  CRISPR/Cas9 Flexes Its Muscles: In Vivo Somatic Gene Editing for Muscular Dystrophy. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[182]  Teri A Manolio,et al.  Genomewide association studies and assessment of the risk of disease. , 2010, The New England journal of medicine.

[183]  Feng Zhang,et al.  Genome engineering using CRISPR-Cas9 system. , 2015, Methods in molecular biology.

[184]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[185]  D. Noble Conrad Waddington and the origin of epigenetics , 2015, The Journal of Experimental Biology.

[186]  R. Prather,et al.  Gene targeting with zinc finger nucleases to produce cloned eGFP knockout pigs , 2011, Molecular reproduction and development.

[187]  R. Jiang,et al.  Prediction of Deleterious Nonsynonymous Single-Nucleotide Polymorphism for Human Diseases , 2013, TheScientificWorldJournal.

[188]  L. Chasin,et al.  CRISPR‐Cas targeted plasmid integration into mammalian cells via non‐homologous end joining , 2015, Biotechnology and bioengineering.

[189]  K. Campbell,et al.  Association of dystrophin and an integral membrane glycoprotein , 1989, Nature.

[190]  T. Lu,et al.  Tunable and Multifunctional Eukaryotic Transcription Factors Based on CRISPR/Cas , 2013, ACS synthetic biology.

[191]  Alexandro E. Trevino,et al.  Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex , 2014, Nature.

[192]  R. Maehr,et al.  Functional annotation of native enhancers with a Cas9 -histone demethylase fusion , 2015, Nature Methods.

[193]  David R. Liu,et al.  CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes , 2017, Cell.

[194]  Ying Sun,et al.  CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes , 2015, Protein & Cell.

[195]  M. Porteus,et al.  Mammalian gene targeting with designed zinc finger nucleases. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[196]  Feng Zhang,et al.  Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system , 2013, Nucleic acids research.

[197]  Vanja Tadić,et al.  Repurposing the CRISPR-Cas9 system for targeted DNA methylation , 2016, Nucleic acids research.